Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10.
Relationships of nutrition and vitamins to the genesis and prevention of cancer are increasingly evident. In a clinical protocol, 32 patients having -"high-risk"- breast cancer were treated with antioxidants, fatty acids, and 90 mg. of CoQ10. Six of the 32 patients showed partial tumor regression. In one of these 6 cases, the dosage of CoQ10 was increased to 390 mg. In one month, the tumor was no longer palpable and in another month, mammography confirmed the absence of tumor. Encouraged, another case having a verified breast tumor, after non-radical surgery and with verified residual tumor in the tumor bed was then treated with 300 mg. CoQ10. After 3 months, the patient was in excellent clinical condition and there was no residual tumor tissue. The bioenergetic activity of CoQ10, expressed as hematological or immunological activity, may be the dominant but not the sole molecular mechanism causing the regression of breast cancer.
Lockwood
K
K
Pharma Nord, Vejle, Denmark.
Moesgaard
S
S
Folkers
K
K
D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000178:diet therapy / Q000188:drug therapy* / Q000473:pathology; D003067:Coenzymes; D005228:Fatty Acids, Essential / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009747:Nutritional Physiological Phenomena; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017962:alpha-Linolenic Acid / Q000627:therapeutic use
D000975:Antioxidants; D003067:Coenzymes; D005228:Fatty Acids, Essential; D015525:Fatty Acids, Omega-3; D017962:alpha-Linolenic Acid; D014451:Ubiquinone; C024989:coenzyme Q10